X4 Pharma Q3 net loss $21.6M; Phase 3 WHIM data on track for Q4; CMO departure, CCO appointed

X4 Pharmaceuticals, Inc

2022-Q3 EPS reported -$1.32

Net loss of $21.6M for Q3 2022, vs $20.2M in Q3 2021; cash $81.1M as of Sept 30, 2022, sufficient into Q3 2023.
R&D expenses $14.1M, SG&A $6.0M; PIPE financing gross proceeds $55M in July 2022.
Phase 3 4WHIM trial top-line data anticipated Q4 2022; NDA submission early H2 2023 if positive.
Positive Phase 1b data for mavorixafor in chronic neutropenia; trial expanding to Phase 1b/2 in H1 2023.
Mark Baldry appointed CCO; CMO Diego Cadavid to resign by end of 2022, Dr. Murray Stewart interim CMO.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

X4 Pharmaceuticals, Inc reported the third quarter ended September 30, 2022 results: net income $21.6 million.

Period: the third quarter ended September 30, 2022
Net income: $21.6 million
Result: reported results

Exact text from the filing

X4 reported a net loss of $21.6 million for the third quarter of 2022, as compared to $20.2 million for the comparable period in 2021.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

X4 Pharmaceuticals, Inc filing history →

Source: SEC EDGAR

accession 0001628280-22-027967

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.